Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by V. Gaudet
Pss17 - Cost Per Responder Analysis of Brodalumab Compared With Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Canada
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pss32 - Cost-Effectiveness of Brodalumab for the Treatment of Moderate to Severe Plaque Psoriasis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss31 - Cost Per Responder of Secukinumab Compared to Other Biologics in Moderate-To-Severe Plaque Psoriasis From the Private Payer Perspective in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss33 - Secukinumab as First Biologic Treatment: A Cost Per Responder Analysis Compared With Licensed Biologics, for Moderate to Severe Psoriasis in Argentina
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost Per Responder for Ixekizumab and Other Biologic Drugs Approved for the Treatment of Moderate-To-Severe Plaque Psoriasis in Italy
Global and Regional Health Technology Assessment
Health Policy
Population Pharmacokinetics of Brodalumab in Patients With Moderate to Severe Plaque Psoriasis
Basic and Clinical Pharmacology and Toxicology
Medicine
Toxicology
Pharmacology
Pss16 - Cost Per Responder Analysis of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Versus Non-Biologic Systemic Therapy in the Treatment of Moderate to Severe Plaque Psoriasis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-To-Severe Psoriasis in the United States
Dermatology and Therapy
Dermatology
Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis
Archives of Dermatology
Psy103 - Modelling Average Cost and Cost-Per-Responder for Biological Treatments for Moderate-To-Severe Plaque Psoriasis With Dose Escalation and Real-World Drug Survival
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
